论文部分内容阅读
目的比较胸腺肽肠溶片与转移因子口服液治疗糜烂型口腔扁平苔藓(OLP)的疗效。方法糜烂型OLP患者100例随机分成两组,每组50例。胸腺肽组予胸腺肽肠溶片10 mg,po,bid;转移因子组予转移因子口服液10 mL,po,tid。均连续治疗2个月,期间不进行其他任何治疗。观察两组临床疗效和不良反应,并检测患者T细胞亚群及体液免疫功能,治疗6个月后观察复发情况。结果共90例完成试验,每组各45例。治疗2个月后,胸腺肽组总有效率为83%,转移因子组为53%,两组临床疗效差异非常显著(P<0.01)。胸腺肽组CD4+T细胞水平升高0.046±0.048,CD4+/CD8+升高0.12±0.26,与治疗前比较差异非常显著(P<0.01)。转移因子组CD4+T细胞水平略有升高,但与治疗前比较无显著差异(P>0.05),低于胸腺肽组(P<0.01),CD4+/CD8+升高0.09±0.23(P<0.05)。治疗6个月后,胸腺肽组OLP复发率17%,明显低于转移因子组(40%,P<0.05)。两组均无严重不良反应发生。结论胸腺肽肠溶片治疗糜烂型OLP疗效优于转移因子口服液,且可提高患者CD4+T细胞水平。
Objective To compare the efficacy of oral administration of thymosin enteric-coated tablets and transfer factor oral solution in the treatment of erosive oral lichen planus (OLP). Methods 100 patients with erosive OLP were randomly divided into two groups, 50 cases in each group. Thymosin group thymosin enteric-coated tablets 10 mg, po, bid; transfer factor group to transfer factor oral solution 10 mL, po, tid. All patients were treated continuously for 2 months without any other treatment. The clinical efficacy and adverse reactions of the two groups were observed. The T lymphocyte subsets and humoral immunity of the patients were observed. The recurrence was observed after 6 months of treatment. Results A total of 90 patients completed the test, 45 cases in each group. After 2 months of treatment, the total effective rate was 83% in the thymosin group and 53% in the transfer factor group, with significant differences in clinical efficacy between the two groups (P <0.01). The level of CD4 + T cells in thymosin group increased by 0.046 ± 0.048 and that of CD4 + / CD8 + increased by 0.12 ± 0.26, which was significantly different from that before treatment (P <0.01). The levels of CD4 + T cells in transfer factor group increased slightly, but no significant difference compared with before treatment (P> 0.05), lower than those in thymosin group (P <0.01), CD4 + / CD8 + increased 0.09 ± 0.23 . After 6 months of treatment, the recurrence rate of OLP in thymosin group was significantly lower than that in transfer factor group (40%, P <0.05). No serious adverse reactions occurred in both groups. Conclusion The effect of thymosin enteric-coated tablets in the treatment of erosive OLP is better than that of transfer factor oral liquid and can increase the level of CD4 + T cells.